Acrivon Therapeutics (ACRV) Q3 2025 earnings summary

Executive summary

• Focused on developing precision oncology therapies using the AP3 platform, with lead assets ACR-368 (CHK1/CHK2 inhibitor) in Phase 2 for endometrial cancer and ACR-2316 (WEE1/PKMYT1 inhibitor) in Phase 1 for solid tumors predicted sensitive by AP3.

• ACR-368 is in a registrational-intent Phase 2b trial for endometrial cancer, targeting patients with high unmet need, and received FDA Fast Track and Breakthrough Device designations.

• Interim Phase 2 data for ACR-368 showed a 35% confirmed ORR and 80% tumor shrinkage in OncoSignature-positive endometrial cancer patients.

• ACR-2316 demonstrated significant drug target engagement and initial clinical activity, including tumor shrinkage and a confirmed partial response at sub-therapeutic doses.

• Showcased AP3 platform's capabilities at a major oncology conference, highlighting its role in rational drug design.

Financial highlights

• Net loss for Q3 2025: $18.2 million, improved from $22.4 million in Q3 2024.

• Net loss for the nine months ended September 30, 2025: $58.9 million, compared to $57.7 million for the same period in 2024.

• Research and development expenses for the quarter: $13.6 million (down $5.2 million year-over-year), primarily due to fewer milestone payments and prioritization of endometrial cancer.

• General and administrative expenses for the quarter: $6.0 million, consistent year-over-year.

• Cash, cash equivalents, and investments as of September 30, 2025: $134.4 million.

Outlook and guidance

• Existing cash and investments expected to fund operations into Q2 2027.

• Updates on ACR-368 trial and confirmatory trial design, as well as initial clinical data from ACR-2316 Phase 1, anticipated in H2 2025.

• Advancing a new cell cycle drug discovery program toward candidate nomination in 2025.

• Anticipates continued operating losses and increased expenses as clinical and preclinical programs advance.

• Additional funding will be required to support long-term growth and development plans.